Harnessing AI For Drug Development – UK's BenevolentAI And MRCT Link
The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.
You may also be interested in...
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.
Upsher-Smith Laboratories of the US is to buy the UK firm Proximagen for £223 million plus a potential £134 million through contingent value rights (CVRs) based on the success of two drugs in its pipeline.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.